NCT04553081View on ClinicalTrials.gov

2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial

PHASE4RecruitingINTERVENTIONAL

Enrollment

134

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

April 30, 2027

Conditions

HIV-1-infection

Interventions

DRUG

Dual versus triple therapy in treatment of HIV-1 infection.

cfr arm description

Trial Locations (1)

9000

RECRUITING

Ghent University Hospital, Ghent

Sponsors

Collaborators (1)

ViiV Healthcare

All Listed Sponsors

collaborator

ViiV Healthcare

INDUSTRY

lead

University Hospital, Ghent

OTHER

NCT04553081 - 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial | Biotech Hunter | Biotech Hunter